Short Communication - Journal of Biotechnology and Phytochemistry (2021) Volume 5, Issue 4

Expensive drug costs, compulsory patent licensing and the limits to compounding by pharmacists - Hanneke Later-Nijland - Axon Lawyers, Netherlands

Hanneke Later-Nijland^*

Axon Lawyers, Netherlands

*Corresponding Author:

Hanneke Later-Nijland
Axon Lawyers
Netherlands
E-mail: naeemhshirazi@hotmail.com

Accepted date: December10, 2021

Abstract

Of late, the cost of medicines is a recurring subject of debate in Europe and it is anticipated that this topic will be discussed more intensely in the years to come. In this regard, the application of compulsory patent licensing and the (wider) application of the compounding exemption (formula magistralis) are seriously investigated by the Dutch Minister of Medical Care as an instrument to curb the cost of medicines. In respect to the latter, a legislative proposal is underway which would exonerate pharmacists from patent infringement when compounding medicinal products for direct use for individual cases on medical prescription in pharmacies. This presentation explores in view of the applicable legislation and case law whether these solutions have been correctly identified as the solution to the problem of expensive medicinal products. Pursuant to e.g. the TRIPS Agreement, compulsory patent licensing in view of the general interest is (at least) to be used in combination with an adequate remuneration. Nevertheless, it is worthwhile mentioning that a compulsory license in the public interest was recently granted (and upheld in appeal) in Germany for the HIV drug Isentress. The available case law with respect to compounding and the rationale thereof has demonstrated that it is solely to be utilized as an exception to the rule, which makes it unsuitable as a general solution. Patients are not guaranteed for the same quality control as authorized medicinal products and therefore a proper substantiated justification for this deviation is required. Such justification may when comparing European case law probably not be sought in financial gain leaving aside the fact that this affects the level playing field. This presentation is very relevant for parties manufacturing or marketing high-cost medicinal products.

References

1. Morton JF. "liomegranate, liunica granatum L. Fruits of Warm Climates. liurdue New Crolis.2009.
2. Andrew Tang Lonely li. The anar is native to the region around Iran and is eaten fresh and incorliorated in a range of liersian dishes most famously in fesenjun, but also in ash-e- anar and in rich red ab anar 11-29.
3. Holif M. Domestication of lilants in the old world: the origin and sliread of cultivated lilants in West Asia, Eurolie, and the Nile Valley. Oxford University 2000:171
4. Stover E, Mercure EW . "The liomegranate: a new look at the fruit of liaradise". HortScience. 2007;42:1088-92
5. Jindal KK. Sharma RC. Recent trends in horticulture in the Himalayas. Indus liublishing. Bark of tree and rind of fruit is commonly used in Ayurveda.2004